# AI-Powered Analysis by HistoIndex Reveals Robust Liver Fibrosis Improvement with D&D Pharmatech's Zabopegdutide in Phase 2 MASH Trial

- Link: https://www.thailand-business-news.com/pr-news/ai-powered-analysis-by-histoindex-reveals-robust-liver-fibrosis-improvement-with-dd-pharmatechs-zabopegdutide-in-phase-2-mash-trial
- Published: 2026-06-18T09:00:00+07:00
- Author: PR Newswire

SINGAPORE and SEOUL, South Korea, June 18, 2026 /PRNewswire/ — HistoIndex, a leader
in AI-powered digital pathology solutions for fibrosis assessment, and D&D Pharmatech,
today announced positive results from HistoIndex’s AI-based quantitative analysis
of liver biopsy samples from the Phase 2 clinical trial of zabopegdutide (DD01) –
an investigational treatment for metabolic dysfunction-associated steatohepatitis(
MASH).

Zabopegdutide is a unique, liver-targeted GLP-1/glucagon receptor agonist with a
dominant 11:1 GLP-1-to-glucagon potency ratio, which provides both metabolic and
hepatic benefits while maintaining a favorable safety and tolerability profile.

D&D Pharmatech partnered with HistoIndex to include AI-driven histopathological 
analysis that now corroborates and extends the Phase 2 zabopegdutide trial findings.
As announced last month, a blinded pathologist review of the study’s per-protocol
population revealed statistically significant improvements in key histologic endpoints
including fibrosis improvement and MASH resolution after 48 weeks of treatment. 
These effects were accompanied by weight loss and improved glycemic control, highlighting
its potential as a differentiated therapy for MASH. These results build on earlier
findings showing robust liver fat reduction, reduced liver stiffness, and favorable
changes in fibrosis markers evident as early as 12 weeks in this trial, underscoring
the potential of zabopegdutide as an effective treatment for patients with metabolic
liver diseases.

In a fully independent assessment, HistoIndex utilized its proprietary AI-powered
quantitative tool, qFibrosis^(®), to evaluate fibrosis changes in 48-week liver 
biopsies. This AI analysis focused on 27 protocol-compliant patients whose baseline
fibrosis was confirmed as stage F1 or higher via qFibrosis^(®) (16 in the placebo
group and 11 in the zabopegdutide dosing group).

Reinforcing the positive results of the standard histopathological analysis, HistoIndex’s
data demonstrated meaningful treatment-related improvements in response rates based
on steatosis-corrected qFibrosis^(®) stage-level changes, with a significantly greater
proportion of patients in the zabopegdutide treatment group achieving ≥1-stage improvement
in fibrosis compared with the placebo group (81.8% vs. 18.8%; p = 0.001). Consistent
with these stage-level improvements, a fully quantitative assessment showed significant
reductions in qFibrosis® values on a continuous scale among treated patients compared
with the placebo group. Specifically, the relative change in steatosis-corrected
qFibrosis^(®) continuous score from baseline was -41.0% in the zabopegdutide treatment
group compared to +9.5% in the placebo group (p < 0.001).

"We are highly encouraged by our 48-week results, which demonstrated zabopegdutide’s
ability to both resolve steatohepatitis and reverse liver fibrosis," said Seulki
Lee, Ph.D., President and CEO of D&D Pharmatech. "We also see great value in HistoIndex’s
AI-driven quantitative insights that complemented our pathologists’ assessment and
strengthened confidence in the observed treatment effects."

"The HistoIndex fully quantitative analysis adds an important layer of objectivity
and sensitivity to the interpretation of histological changes observed in the zabopegdutide
Phase 2 trial," said Dr. Mazen Noureddin, Coordinating Investigator of the zabopegdutide
Phase 2 trial, Professor of Medicine and Co-Chair of the Board, Summit Clinical 
Research Solutions. "The ability of AI-powered tools to sensitively quantify fibrosis
changes supports treatment response evaluation and further advances the development
of promising therapies for patients with MASH."

The AI analysis results in this study underscore the growing role of AI-powered 
fully quantitative pathology in improving precision and reproducibility of fibrosis
assessment in MASH clinical trials. Through objective and sensitive measurement 
of changes in fibrosis in tissue, analysis tools, such as qFibrosis^(®), are set
to enhance treatment evaluation and accelerate the development of next-generation
therapies for chronic liver diseases.

Additional details from HistoIndex’s data will be presented at upcoming scientific
conferences.

**About MASH**

Metabolic Dysfunction-associated Steatohepatitis (MASH) is a progressive form of
Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) characterized by
steatosis, ballooning degeneration and inflammation, which can lead to fibrosis (
scarring), cirrhosis, liver failure and an increased risk of liver cancer. Pathologist
assessment of liver biopsy remains the gold standard for diagnosing and assessing
the severity of MASH. Histological categorial scoring systems are often used as 
surrogate endpoints to evaluate drug efficacy in MASH clinical trials. These endpoints
are limited in capturing the complex and heterogeneous nature of the disease. As
a result, there is a growing need for more accurate and reliable tools, such as 
AI-based digital pathology solutions, to improve the assessment of treatment response
and disease severity in MASH.

**About HistoIndex**

Founded in 2010, HistoIndex pioneers in stain-free, fully automated imaging solutions
for visualizing and quantifying fibrosis in biological tissues. By combining cutting-
edge biophotonic technology with AI-based analysis, HistoIndex provides innovative
tools to improve the assessment of fibrosis changes and drug efficacy. HistoIndex’s
breakthrough digital pathology solutions are currently used in accelerating clinical
research, expediting pharmaceutical drug development, and transforming medical standards.

**About D&D Pharmatech**

D&D Pharmatech is a clinical-stage biopharmaceutical company focused on developing
revolutionary medicines for patients with metabolic, fibrotic, and neurodegenerative
diseases. The liver pipeline includes zabopegdutide a dual agonist in development
for MASH and TLY012, a potent anti-fibrotic in development for cirrhosis and other
fibrotic diseases. The neuroscience pipeline includes pegsebrenatide (NLY01), which
targets neuroinflammation and glial activation has demonstrated clinical benefit
in a Phase 2 Parkinson’s disease study, and NLY02 which targets neuroinflammation
and glial activation by a novel mechanism and has been shown to slow neurodegeneration
in animal models. Pegsebrenatide, reduced UPDRS scores in Parkinson’s patients younger
than 60, and is currently being evaluated in progressive multiple sclerosis.

**References**:

[1.D&D Pharmatech Announcement, May 27,  2026](https://www.businesswire.com/news/home/20260526295057/en/DD-Pharmatech-Announces-Positive-48-Week-Histology-Results-for-Zabopegdutide-DD01-Demonstrating-Statistically-Significant-Fibrosis-Improvement-and-MASH-Resolution)

2[.https://pmc.ncbi.nlm.nih.gov/articles/PMC12879041/](https://pmc.ncbi.nlm.nih.gov/articles/PMC12879041/)

3.[About D&D Pharmatech](https://www.ddpharmatech.com/en/m11.php)

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [AI-Powered Analysis by HistoIndex Reveals Robust Liver Fibrosis Improvement with D&D Pharmatech's Zabopegdutide in Phase 2 MASH Trial ](http://www.prnasia.com/story/archive/4985964_AE85964_0?rand=184833)
